|Articles|March 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2001
  • Volume 0
  • Issue 0

Research: New Horizons

Author(s)Kevin Gopal

London, UK-Changes to the law on human embryo research could herald a new era for UK biotech research. The government feared its proposals to allow the cloning of embryos as sources for stem cells for research would be thrown out by the House of Lords-where a powerful body of opinion holds that they represent a slippery slope toward reproductive cloning-but the proposals passed by a surprisingly large majority.

Articles in this issue

over 25 years ago

Earnings: Tough Times Ahead

over 25 years ago

Outbreak: Anthrax Alarm

over 25 years ago

Patents: China on the Genome Map

over 25 years ago

Privacy, Pediatrics, and Policy

over 25 years ago

Lilly's International Family

over 25 years ago

Update: Punishment and Reprieve

over 25 years ago

Shortage: Vaccine Worries

over 25 years ago

Gateway to Japan

over 25 years ago

Surrounded

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.